Tiziana Life Sciences Ltd (TLSA) 10-Year Financial Performance & Capital Metrics

TLSA • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutTiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.Show more

Revenue $0
EBITDA -$16M +12.4%
Net Income -$12M +32.9%
EPS (Diluted) -0.22 +35.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -250.49% -77.7%
ROIC -481.72% -14.5%
Debt/Equity 0.03 -39.6%
Interest Coverage -2632.33 -46.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 17 (bottom 17%)
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Expensive at 19.6x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-56.61%

EPS CAGR

10Y-

5Y-

3Y-

TTM-70.78%

ROCE

10Y Avg-431.28%

5Y Avg-133.31%

3Y Avg-172.91%

Latest-329.69%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-	-	-	-
Operating Expenses+	8.61M	7.29M	8.25M	7.82M	7.77M	28.03M	27.37M	14.59M	17.98M	15.79M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	0	0	0	0	0	13.21M	855K	0	0	0
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	6.29M	2.96M	4.67M	4.34M	2.91M	5.99M	13.21M	12.96M	8.11M	5.23M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	2.33M	4.33M	3.57M	3.48M	4.86M	8.82M	13.31M	1.63M	9.87M	10.56M
Operating Income+	-8.61M	-7.29M	-8.25M	-7.82M	-7.77M	-28.03M	-27.37M	-14.59M	-17.98M	-15.79M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-2.12%	0.15%	-0.13%	0.05%	0.01%	-2.61%	0.02%	0.47%	-0.23%	0.12%
EBITDA+	-8.61M	-7.28M	-8.23M	-7.81M	-7.58M	-27.94M	-27.23M	-14.54M	-17.89M	-15.67M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-1.42%	0.15%	-0.13%	0.05%	0.03%	-2.69%	0.03%	0.47%	-0.23%	0.12%
D&A (Non-Cash Add-back)	0	8K	11K	12.61K	198K	89.76K	141K	51K	96K	124K
EBIT	0	-7.29M	-8.25M	-7.82M	-7.77M	-27.98M	-26.48M	-15.39M	-17.23M	-16.74M
Net Interest Income+	0	0	0	0	-72K	-312K	-176K	-7K	1.14M	808K
Interest Income	0	0	0	0	1K	8K	0	0	1.15M	814K
Interest Expense	18K	9K	9K	9.46K	73K	320K	176K	7K	10K	6K
Other Income/Expense	-18K	-9K	-9K	-8.67K	-73K	-312K	717K	-811K	742K	-952K
Pretax Income+	-8.63M	-7.3M	-8.26M	-7.83M	-7.85M	-28.34M	-26.66M	-15.4M	-17.24M	-16.75M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	-89K	-1.49M	-1.53M	-540K	-2.21M	-3.24M	0	449K	-4.88M
Effective Tax Rate %	1%	0.99%	0.82%	0.8%	0.93%	0.92%	0.88%	1%	1.03%	0.71%
Net Income+	-8.63M	-7.21M	-6.77M	-6.3M	-7.31M	-26.13M	-23.42M	-15.4M	-17.69M	-11.86M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.46%	0.16%	0.06%	0.07%	-0.16%	-2.58%	0.1%	0.34%	-0.15%	0.33%
Net Income (Continuing)	-8.63M	-7.21M	-6.77M	-6.3M	-7.31M	-26.13M	-23.42M	-15.4M	-17.69M	-11.86M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.18	-0.14	-0.12	-0.09	-0.11	-0.54	-0.48	-0.30	-0.34	-0.22
EPS Growth %	0.71%	0.22%	0.14%	0.23%	-0.19%	-3.91%	0.11%	0.38%	-0.13%	0.35%
EPS (Basic)	-0.18	-0.14	-0.12	-0.09	-0.11	-0.54	-0.48	-0.30	-0.34	-0.22
Diluted Shares Outstanding	46.8M	53.2M	58.49M	68.24M	68.24M	48.65M	48.97M	50.76M	50.76M	53.34M
Basic Shares Outstanding	46.8M	53.2M	58.49M	68.24M	68.24M	48.65M	48.97M	50.76M	50.76M	53.34M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	9.25M	5.02M	1.81M	5.45M	1.14M	70.18M	48.68M	24.28M	7.34M	7.51M
Cash & Short-Term Investments	8.9M	4.7M	48K	4.18M	153K	65.82M	42.19M	18.12M	1.18M	3.72M
Cash Only	8.9M	4.7M	48K	4.18M	153K	65.82M	42.19M	18.12M	1.18M	3.72M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	3.78M	5.27M	5.86M	6.05M	3.69M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	-2.28K	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	347K	320K	1.76M	1.27M	991K	193K	0	0	0	0
Total Non-Current Assets+	0	28K	18K	5.52K	664K	480K	147K	2.19M	4.85M	3.78M
Property, Plant & Equipment	0	28K	18K	5.52K	334K	359.51K	17K	389K	293K	187K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	-35.59K	0	0	0	0
Intangible Assets	0	0	0	0	0	132.59K	130K	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	1.81M	4.55M	3.59M
Other Non-Current Assets	0	0	0	0	330K	23.49K	0	0	0	0
Total Assets+	9.25M	5.05M	1.83M	5.45M	1.81M	70.66M	48.83M	26.48M	12.18M	11.28M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	2.76%	-0.45%	-0.64%	1.98%	-0.67%	38.08%	-0.31%	-0.46%	-0.54%	-0.07%
Total Current Liabilities+	746K	1.74M	3.51M	5.04M	5.58M	7.98M	7.55M	6.66M	6.54M	7.35M
Accounts Payable	0	0	0	0	0	3.37M	4.41M	4.96M	4.14M	5.58M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	216K	225K	234K	244.3K	212K	2.31M	1.35M	122K	138K	106K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	216K	299K	505K	1.93M	5.37M	590.59K	-1.34M	-113K	-124K	-94K
Current Ratio	12.40x	2.89x	0.52x	1.08x	0.21x	8.79x	6.45x	3.64x	1.12x	1.02x
Quick Ratio	12.40x	2.89x	0.52x	1.08x	0.21x	8.79x	6.45x	3.64x	1.12x	1.02x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	530K	1.44M	3.01M	3.11M	411K	290K	0	243K	109K	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	289.79K	0	243K	109K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	530K	1.44M	3.01M	3.11M	411K	207	0	0	0	0
Total Liabilities	746K	1.74M	3.51M	5.04M	5.99M	8.27M	7.55M	6.91M	6.65M	7.35M
Total Debt+	216K	225K	234K	244.3K	623K	555K	1.35M	365K	247K	106K
Net Debt	-8.69M	-4.48M	186K	-3.94M	470K	-65.27M	-42.19M	-17.76M	-936K	-3.62M
Debt / Equity	0.03x	0.07x	-	0.60x	-	0.01x	0.03x	0.02x	0.04x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-478.56x	-809.78x	-916.22x	-827.33x	-106.48x	-87.58x	-155.53x	-2083.71x	-1798.40x	-2632.33x
Total Equity+	8.5M	3.31M	-1.68M	409.01K	-4.18M	62.39M	41.28M	19.57M	5.54M	3.94M
Equity Growth %	3.79%	-0.61%	-1.51%	1.24%	-11.22%	15.92%	-0.34%	-0.53%	-0.72%	-0.29%
Book Value per Share	0.18	0.06	-0.03	0.01	-0.06	1.28	0.84	0.39	0.11	0.07
Total Shareholders' Equity	8.5M	3.31M	-1.68M	409.01K	-4.18M	45.71M	41.28M	19.57M	5.54M	3.94M
Common Stock	9.38M	2.83M	3.75M	6.77M	4.1M	97K	102K	102K	103K	111K
Retained Earnings	-12.24M	11.04M	-29.75M	-39.9M	-43.15M	-84.65M	-108.06M	-116.26M	-133.68M	-144.83M
Treasury Stock	0	0	0	0	0	0	0	-1.32M	-1.57M	0
Accumulated OCI	0	-8K	-19K	-30.73K	-35K	-52K	119.15M	115.57M	117.06M	116.99M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.7M	-5.62M	-5.68M	-3.63M	-5.29M	-8.76M	-16.13M	-15.99M	-12.42M	-1.22M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-1.46%	0.01%	-0.01%	0.36%	-0.46%	-0.65%	-0.84%	0.01%	0.22%	0.9%
Net Income	-8.92M	-7.92M	-6.57M	-6.26M	-7.26M	-19.17M	-17.36M	-12.55M	-14M	-9.48M
Depreciation & Amortization	0	8.79K	10.68K	12.62K	194.77K	65.93K	104.52K	41.57K	75.97K	99.09K
Stock-Based Compensation	0	0	0	0	0	0	0	0	0	0
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	3.32M	1.35M	-895.98K	1.08M	1.55M	10.56M	1.7M	-2.53M	2.75M	8.6M
Working Capital Changes	-93.05K	951.66K	1.78M	1.53M	223.59K	-215.69K	-573.01K	-948.89K	-1.25M	-441.1K
Change in Receivables	-158.18K	0	38.83K	-142K	-99.37K	-342.85K	317.27K	-127.17K	-1.14M	-1.11M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	0	0	0	0
Cash from Investing+	0	-276.93K	-970	0	-2.98K	-93.25K	96.36K	-3.26M	-991.57K	-56.73K
Capital Expenditures	0	-38.46K	-970	0	-2.98K	-93.25K	-16.31K	0	0	-15.18K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	112.67K	-1.08M	-200.21K	10.45K
Cash from Financing+	12.56M	1.28M	1.16M	7.96M	1.31M	54.12M	-17.05K	-44.84K	31.65K	3.6M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-750.61K	0	0	0	-156.02K	-203.45K	-112.67K	-44.84K	-94.17K	28.33K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.7M	-5.65M	-5.68M	-3.63M	-5.29M	-8.76M	-16.15M	-15.99M	-12.42M	-1.23M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-1.46%	0.01%	-0%	0.36%	-0.46%	-0.65%	-0.84%	0.01%	0.22%	0.9%
FCF per Share	-0.12	-0.11	-0.10	-0.05	-0.08	-0.18	-0.33	-0.31	-0.24	-0.02
FCF Conversion (FCF/Net Income)	0.66x	0.78x	0.84x	0.58x	0.72x	0.34x	0.69x	1.04x	0.70x	0.10x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-167.92%	-121.98%	-830.17%	-1540.08%	-	-89.79%	-45.18%	-50.61%	-140.92%	-250.49%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-4572.49%	-966.81%	-420.58%	-481.72%
Debt / Equity	0.03x	0.07x	-	0.60x	-	0.01x	0.03x	0.02x	0.04x	0.03x
Interest Coverage	-478.56x	-809.78x	-916.22x	-827.33x	-106.48x	-87.58x	-155.53x	-2083.71x	-1798.40x	-2632.33x
FCF Conversion	0.66x	0.78x	0.84x	0.58x	0.72x	0.34x	0.69x	1.04x	0.70x	0.10x

Frequently Asked Questions

Growth & Financials

Tiziana Life Sciences Ltd (TLSA) grew revenue by 0.0% over the past year. Growth has been modest.

Tiziana Life Sciences Ltd (TLSA) reported a net loss of $34.2M for fiscal year 2024.

Dividend & Returns

Tiziana Life Sciences Ltd (TLSA) has a return on equity (ROE) of -250.5%. Negative ROE indicates the company is unprofitable.

Tiziana Life Sciences Ltd (TLSA) had negative free cash flow of $13.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Tiziana Life Sciences Ltd (TLSA) 10-Year Financial Performance & Capital Metrics

TLSA • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0
EBITDA -$16M +12.4%
Net Income -$12M +32.9%
EPS (Diluted) -0.22 +35.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -250.49% -77.7%
ROIC -481.72% -14.5%
Debt/Equity 0.03 -39.6%
Interest Coverage -2632.33 -46.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 17 (bottom 17%)
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Expensive at 19.6x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-56.61%

EPS CAGR

10Y-

5Y-

3Y-

TTM-70.78%

ROCE

10Y Avg-431.28%

5Y Avg-133.31%

3Y Avg-172.91%

Latest-329.69%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-	-	-	-
Operating Expenses+	8.61M	7.29M	8.25M	7.82M	7.77M	28.03M	27.37M	14.59M	17.98M	15.79M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	0	0	0	0	0	13.21M	855K	0	0	0
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	6.29M	2.96M	4.67M	4.34M	2.91M	5.99M	13.21M	12.96M	8.11M	5.23M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	2.33M	4.33M	3.57M	3.48M	4.86M	8.82M	13.31M	1.63M	9.87M	10.56M
Operating Income+	-8.61M	-7.29M	-8.25M	-7.82M	-7.77M	-28.03M	-27.37M	-14.59M	-17.98M	-15.79M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-2.12%	0.15%	-0.13%	0.05%	0.01%	-2.61%	0.02%	0.47%	-0.23%	0.12%
EBITDA+	-8.61M	-7.28M	-8.23M	-7.81M	-7.58M	-27.94M	-27.23M	-14.54M	-17.89M	-15.67M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-1.42%	0.15%	-0.13%	0.05%	0.03%	-2.69%	0.03%	0.47%	-0.23%	0.12%
D&A (Non-Cash Add-back)	0	8K	11K	12.61K	198K	89.76K	141K	51K	96K	124K
EBIT	0	-7.29M	-8.25M	-7.82M	-7.77M	-27.98M	-26.48M	-15.39M	-17.23M	-16.74M
Net Interest Income+	0	0	0	0	-72K	-312K	-176K	-7K	1.14M	808K
Interest Income	0	0	0	0	1K	8K	0	0	1.15M	814K
Interest Expense	18K	9K	9K	9.46K	73K	320K	176K	7K	10K	6K
Other Income/Expense	-18K	-9K	-9K	-8.67K	-73K	-312K	717K	-811K	742K	-952K
Pretax Income+	-8.63M	-7.3M	-8.26M	-7.83M	-7.85M	-28.34M	-26.66M	-15.4M	-17.24M	-16.75M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	-89K	-1.49M	-1.53M	-540K	-2.21M	-3.24M	0	449K	-4.88M
Effective Tax Rate %	1%	0.99%	0.82%	0.8%	0.93%	0.92%	0.88%	1%	1.03%	0.71%
Net Income+	-8.63M	-7.21M	-6.77M	-6.3M	-7.31M	-26.13M	-23.42M	-15.4M	-17.69M	-11.86M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.46%	0.16%	0.06%	0.07%	-0.16%	-2.58%	0.1%	0.34%	-0.15%	0.33%
Net Income (Continuing)	-8.63M	-7.21M	-6.77M	-6.3M	-7.31M	-26.13M	-23.42M	-15.4M	-17.69M	-11.86M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.18	-0.14	-0.12	-0.09	-0.11	-0.54	-0.48	-0.30	-0.34	-0.22
EPS Growth %	0.71%	0.22%	0.14%	0.23%	-0.19%	-3.91%	0.11%	0.38%	-0.13%	0.35%
EPS (Basic)	-0.18	-0.14	-0.12	-0.09	-0.11	-0.54	-0.48	-0.30	-0.34	-0.22
Diluted Shares Outstanding	46.8M	53.2M	58.49M	68.24M	68.24M	48.65M	48.97M	50.76M	50.76M	53.34M
Basic Shares Outstanding	46.8M	53.2M	58.49M	68.24M	68.24M	48.65M	48.97M	50.76M	50.76M	53.34M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	9.25M	5.02M	1.81M	5.45M	1.14M	70.18M	48.68M	24.28M	7.34M	7.51M
Cash & Short-Term Investments	8.9M	4.7M	48K	4.18M	153K	65.82M	42.19M	18.12M	1.18M	3.72M
Cash Only	8.9M	4.7M	48K	4.18M	153K	65.82M	42.19M	18.12M	1.18M	3.72M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	3.78M	5.27M	5.86M	6.05M	3.69M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	-2.28K	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	347K	320K	1.76M	1.27M	991K	193K	0	0	0	0
Total Non-Current Assets+	0	28K	18K	5.52K	664K	480K	147K	2.19M	4.85M	3.78M
Property, Plant & Equipment	0	28K	18K	5.52K	334K	359.51K	17K	389K	293K	187K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	-35.59K	0	0	0	0
Intangible Assets	0	0	0	0	0	132.59K	130K	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	1.81M	4.55M	3.59M
Other Non-Current Assets	0	0	0	0	330K	23.49K	0	0	0	0
Total Assets+	9.25M	5.05M	1.83M	5.45M	1.81M	70.66M	48.83M	26.48M	12.18M	11.28M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	2.76%	-0.45%	-0.64%	1.98%	-0.67%	38.08%	-0.31%	-0.46%	-0.54%	-0.07%
Total Current Liabilities+	746K	1.74M	3.51M	5.04M	5.58M	7.98M	7.55M	6.66M	6.54M	7.35M
Accounts Payable	0	0	0	0	0	3.37M	4.41M	4.96M	4.14M	5.58M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	216K	225K	234K	244.3K	212K	2.31M	1.35M	122K	138K	106K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	216K	299K	505K	1.93M	5.37M	590.59K	-1.34M	-113K	-124K	-94K
Current Ratio	12.40x	2.89x	0.52x	1.08x	0.21x	8.79x	6.45x	3.64x	1.12x	1.02x
Quick Ratio	12.40x	2.89x	0.52x	1.08x	0.21x	8.79x	6.45x	3.64x	1.12x	1.02x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	530K	1.44M	3.01M	3.11M	411K	290K	0	243K	109K	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	289.79K	0	243K	109K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	530K	1.44M	3.01M	3.11M	411K	207	0	0	0	0
Total Liabilities	746K	1.74M	3.51M	5.04M	5.99M	8.27M	7.55M	6.91M	6.65M	7.35M
Total Debt+	216K	225K	234K	244.3K	623K	555K	1.35M	365K	247K	106K
Net Debt	-8.69M	-4.48M	186K	-3.94M	470K	-65.27M	-42.19M	-17.76M	-936K	-3.62M
Debt / Equity	0.03x	0.07x	-	0.60x	-	0.01x	0.03x	0.02x	0.04x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-478.56x	-809.78x	-916.22x	-827.33x	-106.48x	-87.58x	-155.53x	-2083.71x	-1798.40x	-2632.33x
Total Equity+	8.5M	3.31M	-1.68M	409.01K	-4.18M	62.39M	41.28M	19.57M	5.54M	3.94M
Equity Growth %	3.79%	-0.61%	-1.51%	1.24%	-11.22%	15.92%	-0.34%	-0.53%	-0.72%	-0.29%
Book Value per Share	0.18	0.06	-0.03	0.01	-0.06	1.28	0.84	0.39	0.11	0.07
Total Shareholders' Equity	8.5M	3.31M	-1.68M	409.01K	-4.18M	45.71M	41.28M	19.57M	5.54M	3.94M
Common Stock	9.38M	2.83M	3.75M	6.77M	4.1M	97K	102K	102K	103K	111K
Retained Earnings	-12.24M	11.04M	-29.75M	-39.9M	-43.15M	-84.65M	-108.06M	-116.26M	-133.68M	-144.83M
Treasury Stock	0	0	0	0	0	0	0	-1.32M	-1.57M	0
Accumulated OCI	0	-8K	-19K	-30.73K	-35K	-52K	119.15M	115.57M	117.06M	116.99M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.7M	-5.62M	-5.68M	-3.63M	-5.29M	-8.76M	-16.13M	-15.99M	-12.42M	-1.22M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-1.46%	0.01%	-0.01%	0.36%	-0.46%	-0.65%	-0.84%	0.01%	0.22%	0.9%
Net Income	-8.92M	-7.92M	-6.57M	-6.26M	-7.26M	-19.17M	-17.36M	-12.55M	-14M	-9.48M
Depreciation & Amortization	0	8.79K	10.68K	12.62K	194.77K	65.93K	104.52K	41.57K	75.97K	99.09K
Stock-Based Compensation	0	0	0	0	0	0	0	0	0	0
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	3.32M	1.35M	-895.98K	1.08M	1.55M	10.56M	1.7M	-2.53M	2.75M	8.6M
Working Capital Changes	-93.05K	951.66K	1.78M	1.53M	223.59K	-215.69K	-573.01K	-948.89K	-1.25M	-441.1K
Change in Receivables	-158.18K	0	38.83K	-142K	-99.37K	-342.85K	317.27K	-127.17K	-1.14M	-1.11M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	0	0	0	0
Cash from Investing+	0	-276.93K	-970	0	-2.98K	-93.25K	96.36K	-3.26M	-991.57K	-56.73K
Capital Expenditures	0	-38.46K	-970	0	-2.98K	-93.25K	-16.31K	0	0	-15.18K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	112.67K	-1.08M	-200.21K	10.45K
Cash from Financing+	12.56M	1.28M	1.16M	7.96M	1.31M	54.12M	-17.05K	-44.84K	31.65K	3.6M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-750.61K	0	0	0	-156.02K	-203.45K	-112.67K	-44.84K	-94.17K	28.33K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.7M	-5.65M	-5.68M	-3.63M	-5.29M	-8.76M	-16.15M	-15.99M	-12.42M	-1.23M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-1.46%	0.01%	-0%	0.36%	-0.46%	-0.65%	-0.84%	0.01%	0.22%	0.9%
FCF per Share	-0.12	-0.11	-0.10	-0.05	-0.08	-0.18	-0.33	-0.31	-0.24	-0.02
FCF Conversion (FCF/Net Income)	0.66x	0.78x	0.84x	0.58x	0.72x	0.34x	0.69x	1.04x	0.70x	0.10x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-167.92%	-121.98%	-830.17%	-1540.08%	-	-89.79%	-45.18%	-50.61%	-140.92%	-250.49%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-4572.49%	-966.81%	-420.58%	-481.72%
Debt / Equity	0.03x	0.07x	-	0.60x	-	0.01x	0.03x	0.02x	0.04x	0.03x
Interest Coverage	-478.56x	-809.78x	-916.22x	-827.33x	-106.48x	-87.58x	-155.53x	-2083.71x	-1798.40x	-2632.33x
FCF Conversion	0.66x	0.78x	0.84x	0.58x	0.72x	0.34x	0.69x	1.04x	0.70x	0.10x

Frequently Asked Questions

Growth & Financials

Tiziana Life Sciences Ltd (TLSA) grew revenue by 0.0% over the past year. Growth has been modest.

Tiziana Life Sciences Ltd (TLSA) reported a net loss of $34.2M for fiscal year 2024.

Dividend & Returns

Tiziana Life Sciences Ltd (TLSA) has a return on equity (ROE) of -250.5%. Negative ROE indicates the company is unprofitable.

Tiziana Life Sciences Ltd (TLSA) had negative free cash flow of $13.6M in fiscal year 2024, likely due to heavy capital investments.